Distribution, molecular landscape and survival correlates of RAS/CBL^MTs. (A) The frequency of gene mutations identified in the MF cohort; red-violet bars identify mutations of the RAS/MAPK pathway genes (ie, NRAS, KRAS, and CBL). (B) Aerogram displaying the percentage of patients with MF, with and without RAS/CBL^MTs (left), and the distribution of patients with NRAS^MTs, KRAS^MTs, and CBL^MTs and multiple RAS/CBL^MTs (right). (C) Kaplan-Meier estimates of OS in the entire MF cohort by the presence or absence of RAS/CBL^MTs. (D) Five-year CuI of leukemic transformation in the entire MF cohort by the presence or absence of RAS/CBL^MTs.